Viridian Therapeutics Inc (VRDN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.51B
Last updated: Nov 17, 2026 at 11:05 AM ET
Viridian Therapeutics Inc (VRDN) Earnings: Report Dates and Results
Viridian Therapeutics (VRDN) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Viridian Therapeutics reported EPS of -$0.81, above the -$1.01 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VRDN has an expected report date of Feb 24, 2027.
VRDN Earnings Call
The latest VRDN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, VRDN beat 19, missed 18 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $25.75M, down 63.5% from $70.57M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.81 | -$1.01 | -$1.26 - -$0.78 | +19.80% | Beat | N/A | 12 | 1 up, 0 down | Nov 4, 2026 | $25.75M |
| Jun 30, 2026 | -$1.05 | -$0.97 | -$1.22 - -$0.87 | -8.25% | Miss | N/A | 11 | 3 up, 2 down | Aug 6, 2026 | $284000 |
| Mar 31, 2026 | -$0.90 | -$1.08 | -$1.29 - -$0.94 | +16.67% | Beat | N/A | 11 | 0 up, 1 down | May 5, 2026 | $141000 |
| Dec 31, 2025 | -$1.08 | -$0.90 | -$1.32 - -$0.59 | -20.00% | Miss | N/A | 12 | 0 up, 2 down | Feb 26, 2026 | $132000 |
| Sep 30, 2025 | -$0.34 | -$0.82 | -$1.30 - -$0.27 | +58.54% | Beat | N/A | 10 | 1 up, 3 down | Nov 5, 2025 | $70.57M |
| Jun 30, 2025 | -$1.00 | -$0.98 | -$1.09 - -$0.81 | -2.04% | Miss | N/A | 12 | 3 up, 5 down | Aug 6, 2025 | $75000 |
| Mar 31, 2025 | -$0.87 | -$0.96 | -$1.28 - -$0.84 | +9.38% | Beat | N/A | 9 | 3 up, 1 down | May 6, 2025 | $72000 |
| Dec 31, 2024 | -$0.81 | -$1.04 | -$1.20 - -$0.84 | +22.43% | Beat | N/A | 12 | 1 up, 6 down | Feb 27, 2025 | $72000 |
| Sep 30, 2024 | -$1.15 | -$1.05 | -$1.17 - -$0.80 | -9.52% | Miss | N/A | 14 | 0 up, 0 down | Nov 12, 2024 | $86000 |
| Jun 30, 2024 | -$1.02 | -$0.92 | -$1.14 - -$0.69 | -10.87% | Miss | N/A | 15 | 0 up, 0 down | Aug 8, 2024 | $72000 |
| Mar 31, 2024 | -$0.79 | -$1.10 | -$1.36 - -$0.81 | +28.18% | Beat | N/A | 12 | 0 up, 0 down | May 8, 2024 | $72000 |
| Dec 31, 2023 | -$1.35 | -$1.03 | -$1.17 - -$0.84 | -31.07% | Miss | N/A | 13 | 0 up, 0 down | Feb 27, 2024 | $72000 |
| Sep 30, 2023 | -$1.09 | -$1.24 | -$1.44 - -$0.91 | +12.10% | Beat | N/A | 14 | 0 up, 0 down | Nov 13, 2023 | $72000 |
| Jun 30, 2023 | -$1.27 | -$1.26 | -$1.69 - -$0.97 | -0.79% | Miss | N/A | 14 | 1 up, 0 down | Aug 8, 2023 | $72000 |
| Mar 31, 2023 | -$1.61 | -$1.02 | -$1.23 - -$0.82 | -57.84% | Miss | N/A | 10 | 0 up, 0 down | May 9, 2023 | $98000 |
| Dec 31, 2022 | -$1.13 | -$0.72 | -$0.94 - -$0.50 | -56.94% | Miss | N/A | 10 | 0 up, 0 down | Mar 8, 2023 | $105000 |
| Sep 30, 2022 | -$0.86 | -$1.01 | -$1.24 - -$0.48 | +14.85% | Beat | N/A | 8 | 0 up, 0 down | Nov 14, 2022 | $1.20M |
| Jun 30, 2022 | -$1.06 | -$0.90 | -$1.05 - -$0.51 | -17.78% | Miss | N/A | 7 | 0 up, 0 down | Aug 15, 2022 | $256000 |
| Mar 31, 2022 | -$0.98 | -$1.08 | -$1.32 - -$0.90 | +9.26% | Beat | N/A | 5 | 0 up, 0 down | May 12, 2022 | $216000 |
| Dec 31, 2021 | -$1.32 | -$0.99 | -$1.43 - -$0.33 | -33.33% | Miss | N/A | 7 | 0 up, 0 down | Mar 10, 2022 | $214000 |
| Sep 30, 2021 | -$1.25 | -$1.34 | -$2.29 - -$0.26 | +6.72% | Beat | N/A | 6 | N/A | Nov 4, 2021 | $208000 |
| Jun 30, 2021 | -$2.21 | -$1.40 | -$2.65 - -$0.32 | -57.86% | Miss | N/A | 5 | N/A | Aug 11, 2021 | $1.09M |
| Mar 31, 2021 | -$2.91 | -$0.76 | -$1.65 - -$0.30 | -282.89% | Miss | N/A | 5 | N/A | May 6, 2021 | $1.45M |
| Dec 31, 2020 | -$30.74 | -$1.03 | -$1.27 - -$0.19 | N/A | N/A | N/A | 3 | N/A | Mar 25, 2021 | $54000 |
| Sep 30, 2020 | -$1.50 | -$1.99 | N/A | +24.62% | Beat | N/A | N/A | N/A | Nov 10, 2020 | N/A |
| Jun 30, 2020 | -$1.80 | -$2.47 | N/A | +27.13% | Beat | N/A | N/A | N/A | Aug 5, 2020 | $168000 |
| Mar 31, 2020 | -$2.70 | -$2.88 | N/A | +6.25% | Beat | N/A | N/A | N/A | May 7, 2020 | $828000 |
| Dec 31, 2019 | -$4.65 | -$3.78 | N/A | -23.02% | Miss | N/A | N/A | N/A | Mar 11, 2020 | $880000 |
| Sep 30, 2019 | -$5.40 | -$4.44 | N/A | -21.62% | Miss | N/A | N/A | N/A | Nov 7, 2019 | $695000 |
| Jun 30, 2019 | -$4.35 | -$5.45 | N/A | +20.18% | Beat | N/A | N/A | N/A | Aug 7, 2019 | $2.51M |
| Mar 31, 2019 | -$5.70 | -$5.16 | N/A | -10.47% | Miss | N/A | N/A | N/A | May 8, 2019 | $372000 |
| Dec 31, 2018 | -$4.95 | -$4.62 | N/A | -7.14% | Miss | N/A | N/A | N/A | Mar 13, 2019 | $476000 |
| Sep 30, 2018 | -$4.35 | -$4.76 | N/A | +8.61% | Beat | N/A | N/A | N/A | Nov 7, 2018 | $944000 |
| Jun 30, 2018 | -$4.35 | -$4.35 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 7, 2018 | $2.18M |
| Mar 31, 2018 | -$2.70 | -$3.67 | N/A | +26.43% | Beat | N/A | N/A | N/A | May 9, 2018 | $4.78M |
| Dec 31, 2017 | -$4.35 | -$4.76 | N/A | +8.61% | Beat | N/A | N/A | N/A | Mar 14, 2018 | $1.19M |
| Sep 30, 2017 | -$4.05 | -$5.70 | N/A | +28.95% | Beat | N/A | N/A | N/A | Nov 8, 2017 | $1.63M |
| Jun 30, 2017 | -$5.10 | -$7.05 | N/A | +27.66% | Beat | N/A | N/A | N/A | Aug 11, 2017 | $718000 |
| Mar 31, 2017 | -$9.00 | -$3.60 | N/A | -150.00% | Miss | N/A | N/A | N/A | May 10, 2017 | $462000 |
| Dec 31, 2016 | -$3.45 | -$3.45 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 24, 2017 | $756000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.29, after -$3.77 the year before. It was -$117.15 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.29 | N/A |
| Dec 31, 2024 | -$3.77 | N/A |
| Dec 31, 2023 | -$5.32 | N/A |
| Dec 31, 2022 | -$4.03 | N/A |
| Dec 31, 2021 | -$7.69 | N/A |
| Dec 31, 2020 | -$36.74 | N/A |
| Dec 31, 2019 | -$20.10 | N/A |
| Dec 31, 2018 | -$16.35 | N/A |
| Dec 31, 2017 | -$22.50 | N/A |
| Dec 31, 2016 | -$117.15 | N/A |
Earnings Calls
The only earnings call listed below, 2026Q3 for the period ended Sep 30, 2026, runs about 6,100 words across 21 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,102 | 21 |
2026Q3 Earnings Call
Opening remarks
Greg Rossino Senior Director of Investor Relations Thank you, Operator, and good morning, everyone. Thank you for joining us to discuss Viridian's third quarter 2026 financial results and recent business updates. You can access the press release and the slides for today's call on the Investors page of our corporate website at viridiantherapeutics.com. Before we begin, I would like to remind everyone that today's call and webcast will contain forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. A description of these risks can be found in the forward-looking statement section disclaimer in the press release and slides issued today, as well as our SEC filings, including our quarterly report on Form 10-Q. With me today are Steve Mahoney, our President and Chief Executive Officer, Tony Casciano, our Chief Commercial Officer, and Seth Harmon, our Chief Financial Officer. Shan Wu, our Chief Business Officer, will join us for Q&A. With that, I will turn the call over to Steve.
Steve Mahoney President and Chief Executive Officer Thanks, Greg, and good morning, everyone. Thank you for joining us to discuss the results from our first quarter of Lumvoa launch in thyroid eye disease. As spelled out in our earnings release earlier this morning, it has been a very strong start, and the Viridian team has done another excellent job executing across the board. Lumvoa generated $24.7 million in net product revenue, and we had more than 100 patients on therapy as of September 30th. This is a very encouraging start to the launch and certainly has exceeded expectations. It is still early in the launch cycle, but we believe these results are a testament to Lumvoa's compelling product profile and the readiness and execution of our entire organization since day one of launch. Before we provide more color on the Lumvoa launch, I want to highlight the emerging Viridian pipeline, which we believe will drive the next chapter of Viridian's growth in autoimmune disease. First, we're on track to submit our BLA for elegrobart in the first quarter of 2027. Ellie is our next-generation subcutaneous anti-IGF-1R. Based on our phase III results, Ellie has the potential to further improve the TED patient experience, and we believe that it will encourage more patients to seek treatment with at-home self-administration as infrequently as every eight weeks. Later this quarter, we also look forward to sharing first-in-human results for VRDN-008. 008 is a half-life-extended FcRn inhibitor and is another example of a product candidate designed to reduce treatment burden with less frequent dosing while also providing sustained disease control. We're also making strong progress with our anti-TSHR product candidate, now called VRDN-292, which we believe has the potential to be best in class.
Frequently Asked Questions About VRDN
When is Viridian Therapeutics's next earnings date?
Viridian Therapeutics's next earnings report is expected for Feb 24, 2027.
Did VRDN beat earnings estimates last quarter?
Yes. Viridian Therapeutics reported EPS of -$0.81 for the quarter ended Sep 30, 2026, above the -$1.01 estimate, a 19.80% surprise.
What EPS do analysts expect from VRDN next quarter?
The consensus EPS estimate for Viridian Therapeutics for the quarter ending Dec 31, 2026 is -$0.72 from 16 analysts, with estimates from -$0.83 to -$0.61.
How often does VRDN beat earnings estimates?
Viridian Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +12.07%.
VRDN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors